Loteprednol
Showing 1 - 25 of 67
Corneal Endothelial Dystrophy, Corneal Edema Trial in Indianapolis (loteprednol etabonate 0.25% ophthalmic suspension)
Active, not recruiting
- Corneal Endothelial Dystrophy
- Corneal Edema
- loteprednol etabonate 0.25% ophthalmic suspension
-
Indianapolis, IndianaPrice Vision Group
Jan 6, 2023
Dry Eye Trial in Hemet, Laguna Hills, Brecksville (Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free)
Completed
- Dry Eye
- Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free
-
Hemet, California
- +2 more
Dec 30, 2022
Age-Related Macular Degeneration Trial (Loteprednol Etabonate Ophthalmic Gel [Lotemax], Nepafenac Ophthalmic 0.3% Ophthalmic
Not yet recruiting
- Age-Related Macular Degeneration
- Loteprednol Etabonate Ophthalmic Gel [Lotemax]
- +2 more
- (no location specified)
Sep 14, 2022
Vernal Keratoconjunctivitis, Cyclosporine 0.05% Eye Drops Trial in Nanchang (Cyclosporine 0.05% eye drops, Loteprednol Etabonate
Completed
- Vernal Keratoconjunctivitis
- Cyclosporine 0.05% Eye Drops
- Cyclosporine 0.05% eye drops
- Loteprednol Etabonate 0.5% and Tobramycin Eye Drops 0.3%
-
Nanchang, Jiangxi, Chinathe Second Affiliated Hospital of Nanchang University
Apr 28, 2022
Intraocular Pressure, Corneal Opacity Trial in Murray (Loteprednol Etabonate 0.5% Oph Gel, Prednisolone Acetate 1% Oph Susp)
Completed
- Intraocular Pressure
- Corneal Opacity
- Loteprednol Etabonate 0.5% Oph Gel
- Prednisolone Acetate 1% Oph Susp
-
Murray, UtahMoran Eye Center - Midvalley Location
May 4, 2021
Bilateral Conjunctivitis (Disorder) Trial in Pompano Beach (Dexamethasone ophthalmic insert 0.4Mg, 0.2% loteprednol etabonate
Completed
- Bilateral Conjunctivitis (Disorder)
- Dexamethasone ophthalmic insert 0.4Mg
- +2 more
-
Pompano Beach, FloridaClinical Research Center of Florida
Apr 6, 2022
Dry Eye Disease Trial in Boston (Lotemax, Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears), In Vivo Confocal Microscopy
Cataract, Pain, Ocular Inflammation Trial in United States (Loteprednol Etabonate Ophthalmic Gel dosed TID, Loteprednol
Completed
- Cataract
- +2 more
- Loteprednol Etabonate Ophthalmic Gel dosed TID
- +2 more
-
Phoenix, Arizona
- +5 more
Jan 6, 2021
Inflammation, Pain, Cataract Trial in Bridgewater (Loteprednol Etabonate Gel (BID), Loteprednol Etabonate Gel (TID), Vehicle
Completed
- Inflammation
- +2 more
- Loteprednol Etabonate Gel (BID)
- +3 more
-
Bridgewater, New JerseyBausch & Lomb Incorporated
Sep 2, 2020
Inflammation, Pain, Cataract Trial in Bridgewater (Loteprednol Etabonate Gel (BID), Vehicle Gel (BID))
Completed
- Inflammation
- +2 more
- Loteprednol Etabonate Gel (BID)
- Vehicle Gel (BID)
-
Bridgewater, New JerseyBausch & Lomb Incorporated
Sep 2, 2020
Retinal Vein Occlusion, Diabetic Macular Edema Trial in Beverly Hills, Boston (KPI-121 0.25% Ophthalmic Suspension, KPI-121 1.0%
Completed
- Retinal Vein Occlusion
- Diabetic Macular Edema
- KPI-121 0.25% Ophthalmic Suspension
- KPI-121 1.0% Ophthalmic Suspension
-
Beverly Hills, California
- +1 more
Dec 9, 2020
Allergic Conjunctivitis Trial in Andover (Prednisolone Acetate 1%, Prednisolone Acetate 0.12%, Loteprednol Etabonate 0.2%)
Completed
- Allergic Conjunctivitis
- Prednisolone Acetate 1%
- +3 more
-
Andover, MassachusettsOphthalmic Research Associates
Aug 19, 2020
Inflammation Following Ocular Surgery Trial in Multiple Locations (Generic Loteprednol Etabonate, Reference Listed Drug (RLD))
Completed
- Inflammation Following Ocular Surgery
- Generic Loteprednol Etabonate
- Reference Listed Drug (RLD)
-
Multiple Locations, CanadaSandoz Investigative Site
Nov 5, 2019
Ocular Infections, Irritations and Inflammations Trial in United States (KPI-121 0.25%, KPI-121 1.0%, Vehicle of KPI-121 0.25%)
Completed
- Ocular Infections, Irritations and Inflammations
- KPI-121 0.25%
- +3 more
-
Artesia, California
- +22 more
Jan 6, 2021
Recurrent Pterygium of Eye, Steroid-Induced Glaucoma Trial (0.2% loteprednol etabonate, 0.1% dexamethasone)
Completed
- Recurrent Pterygium of Eye
- Steroid-Induced Glaucoma
- 0.2% loteprednol etabonate
- 0.1% dexamethasone
- (no location specified)
Sep 4, 2019
Dry Eye Syndromes, Keratoconjunctivitis Sicca Trial in United States (KPI-121, Placebo)
Completed
- Dry Eye Syndromes
- Keratoconjunctivitis Sicca
- KPI-121
- Placebo
-
Artesia, California
- +10 more
Jan 4, 2021
Post-operative Healing Following Blepharoplasty and Ptosis Repair Trial in La Jolla (Loteprednol etabonate ophthalmic ointment,
Withdrawn
- Post-operative Healing Following Blepharoplasty and Ptosis Repair
- Loteprednol etabonate ophthalmic ointment
- Vehicle Ophthalmic Ointment
-
La Jolla, CaliforniaShiley Eye Center
Jul 31, 2019
Cataract Trial in Rochester (Loteprednol etabonate, Prednisolones acetate)
Completed
- Cataract
- Loteprednol etabonate
- Prednisolones acetate
-
Rochester, New YorkBausch & Lomb Inc
Jun 10, 2019
Allergic Conjunctivitis Trial in Fullerton (bepotastine besilate, 1.5%, Loteprednol etabonate)
Completed
- Allergic Conjunctivitis
- bepotastine besilate, 1.5%
- Loteprednol etabonate
-
Fullerton, California
- +1 more
Jul 16, 2019
Conjunctivitis, Seasonal Allergic, Conjunctivitis, Giant Papillary, Inflammation Trial in Seoul (Loteprednol Etabonate,
Completed
- Conjunctivitis, Seasonal Allergic
- +2 more
- Loteprednol Etabonate
- Prednisolone Acetate 1% Oph Susp
-
Seoul, Korea, Republic ofBausch & Lomb Korea Ltd
Nov 18, 2019
Keratoconjunctivitis Sicca Trial in Irvine (Lotemax, Restasis, Soothe® Lubricant Eye Drops)
Completed
- Keratoconjunctivitis Sicca
- Lotemax
- +2 more
-
Irvine, CaliforniaBausch & Lomb Incorporated
Aug 28, 2019
Post Surgical Ocular Inflammation and Pain Trial in United States (KPI-121 1% Ophthalmic Suspension dosed BID, Vehicle of
Completed
- Post Surgical Ocular Inflammation and Pain
- KPI-121 1% Ophthalmic Suspension dosed BID
- Vehicle of KPI-121 Ophthalmic Suspension dosed BID
-
Chandler, Arizona
- +34 more
Nov 24, 2020